%PDF-1.4
%
41 0 obj
<>
endobj
38 0 obj
<>
endobj
96 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-12-03T10:41:16Z
2024-03-28T12:37:43-07:00
QuarkXPressª: AdobePS 8.6 (219)
2024-03-28T12:37:43-07:00
application/pdf
Heather
2001-374march02
uuid:a452923d-1dd1-11b2-0a00-3d09275d6100
uuid:a452923f-1dd1-11b2-0a00-aa0000000000
endstream
endobj
27 0 obj
<>
endobj
28 0 obj
<>
endobj
42 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
1 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
4 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
12 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
15 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
18 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
118 0 obj
[122 0 R]
endobj
119 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.06 612 -792 re
W n
BT
/CS0 cs 0 0 0 1 scn
/GS1 gs
/TT0 1 Tf
0.02499 Tw 8 0 0 8 74.4 714.5293 Tm
(Moutsopoulos HM. Prevalence of antikeratin antibodies in Greek)Tj
0 -1.25 TD
[(patients with rheumatoid arthritis. )54.9 (A)-219.8 (clinical, serologic, and)]TJ
T*
[(immunogenetic study)64.9 (. J Rheumatol 1995;22:2046-8.)]TJ
-0.00011 Tc -2.175 -1.25 Td
[(36.)-875.1 (Palosuo )17.7 (T)73.9 (,)-0.1 ( Lukka M, )54.8 (Alenius H, Kalkinen N, )54.8 (Aho K, Kurki P)110.7 (.)]TJ
0 Tc 2.175 -1.25 Td
(Purification of filaggrin from human epidermis and measurement of)Tj
T*
(antifilaggrin autoantibodies in sera from patients with rheumatoid)Tj
T*
[(arthritis by an enzyme-linked immunosorbent assay)64.9 (. Int )54.9 (Arch)]TJ
T*
[(Aller)17.8 (gy Immunol 1998;1)36.9 (15:294-302.)]TJ
-2.175 -1.25 Td
[(37.)-875 (Aho K, Palosuo )17.7 (T)74 (, Lukka M, et al. )54.8 (Antifilaggrin antibodies in)]TJ
2.175 -1.25 Td
[(recent-onset arthritis. Scand J Rheumatol 1999;28:1)36.9 (13-6.)]TJ
-2.175 -1.25 Td
[(38.)-875 (V)111.1 (an der Linden S, )17.7 (V)111.1 (alkenbur)17.8 (g HA, Cats )54.8 (A. Evaluation of diagnostic)]TJ
2.175 -1.25 Td
[(criteria for ankylosing spondylitis: )54.8 (A)-219.8 (proposal for modification of)]TJ
T*
[(the New )36.8 (Y)100.1 (ork criteria. )54.8 (Arthritis Rheum 1984;27:361-8.)]TJ
-2.175 -1.25 Td
[(39.)-875 (Altman R, )54.8 (Alarcon G, )54.8 (Appelrouth D, et al. )17.7 (The )54.8 (American College)]TJ
2.175 -1.25 Td
(of Rheumatology criteria for the classification and reporting of)Tj
T*
[(osteoarthritis of the hand. )54.9 (Arthritis Rheum 1990;33:1601-10.)]TJ
-0.00011 Tc -2.175 -1.25 Td
[(40.)-875.1 (Harrison BJ, Symmons DPM, Barret BM, Silman )54.8 (AJ. )17.7 (The)]TJ
2.175 -1.25 Td
[(performance of the 1987 )54.8 (ARA)-220.2 (classification criteria for rheumatoid)]TJ
0 Tc T*
(arthritis in a population based cohort of patients with early)Tj
T*
(inflammatory polyarthritis. J Rheumatol 1998;25:2324-30.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(41.)-875.1 (Juby )54.8 (AG, Davis P)110.7 (, McElhaney JE, Gravenstein S. Prevalence of)]TJ
0 Tc 2.175 -1.25 Td
[(selected autoantibodies in dif)17.8 (ferent elderly populations. Br J)]TJ
T*
[(Rheumatol 1994;33:1)36.9 (121-4.)]TJ
-0.00011 Tc -2.175 -1.25 Td
[(42.)-875.1 (Manoussakis MN, )17.7 (Tzioufas )54.8 (AG, Silis MP)110.7 (, Pange PJE, Goudevenos)]TJ
0 Tc 2.175 -1.25 Td
(J, Moutsopoulos HM. High prevalence of anticardiolipin and other)Tj
T*
(antibodies in a healthy elderly population. Clin Exp Immunol)Tj
0 Tw T*
(1987;69:557-65.)Tj
0.0249 Tw -2.175 -1.25 Td
[(43.)-875 (Maillefert JF)79.8 (, Pfitzenmeyer P)110.8 (, )17.7 (Thenet M. Prevalence of antikeratin)]TJ
2.175 -1.25 Td
(antibodies in an elderly population. J Rheumatol 1999;26:1214-5.)Tj
-0.00011 Tc 30.825 35 Td
[(44.)-875.1 (Alnigenis MN, )17.7 (W)79.7 (arikoo S, Barland P)110.7 (.)-0.1 ( )54.8 (Antiperinuclear factor and)]TJ
0 Tc 2.175 -1.25 Td
(antikeratin antibody: diagnostic use in a clinical laboratory setting)Tj
T*
([letter]. J Rheumatol 2000;27:2056-7.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(45.)-875.1 (Schellekens GA, )17.7 (V)60 (isser H, de Jong BW)91.7 (, et al. )17.7 (The diagnostic)]TJ
0 Tc 2.175 -1.25 Td
(properties of rheumatoid arthritis antibodies recognizing a cyclic)Tj
T*
[(citrullinated peptide. )54.9 (Arthritis Rheum 2000;43:155-63.)]TJ
-0.00011 Tc -2.175 -1.25 Td
[(46.)-875.1 (Girbal-Neuhauser E, Durieux JJ, )54.8 (Arnaud M, et al. )17.7 (The epitopes)]TJ
0 Tc 2.175 -1.25 Td
[(tar)17.8 (geted by the rheumatoid arthritis-associated antifilaggrin)]TJ
T*
(autoantibodies are posttranslationally generated on various sites of)Tj
T*
[(\(pro\)filaggrin by deimination of ar)17.8 (ginine residues. J Immunol)]TJ
0 Tw T*
(1999;162:585-94.)Tj
0.02499 Tw -2.175 -1.25 Td
[(47.)-875 (Schellekens G, de Jong B, van den Hoogen F)79.8 (, van de Putte L, van)]TJ
2.175 -1.25 Td
[(V)111.1 (enrooij )17.8 (W)91.8 (. Citrulline is an essential constituent of antigenic)]TJ
T*
(determinants recognized by rheumatoid arthritis\226specific)Tj
T*
(autoantibodies. J Clin Invest 1998;101:273-81.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(48.)-875.1 (V)111 (an Jaarsveld CHM, ter Bor)17.7 (g EJ, Jacobs JWG, et al. )17.7 (The)]TJ
0 Tc 2.175 -1.25 Td
[(prognostic value of the antiperinuclear factor)39.8 (, anticitrullinated)]TJ
T*
(peptide antibodies and rheumatoid factor in early rheumatoid)Tj
T*
(arthritis. Clin Exp Rheumatol 1999;17:689-97.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(49.)-875.1 (Masson-Bessiere C, Sebbag M, Girbal-Neuhauser E, et al. )17.7 (The)]TJ
2.175 -1.25 Td
[(major synovial tar)17.7 (gets of the rheumatoid arthritis-specific)]TJ
0 Tc T*
(antifilaggrin autoantibodies are deiminated forms of the a and \337)Tj
T*
(chains of fibrin. J Immunol 2001;166:4177-84.)Tj
-2.175 -1.25 Td
[(50.)-875 (Paimela L, Palosuo )17.8 (T)74 (, )54.9 (Aho K, et al. )54.9 (Association of autoantibodies to)]TJ
2.175 -1.25 Td
[(filaggrin with an active disease in early rheumatoid arthritis. )54.9 (Ann)]TJ
T*
(Rheum Dis 2001;60:32-5.)Tj
ET
/CS0 CS 0 0 0 1 SCN
54 54 m
558 54 l
S
BT
/TT1 1 Tf
-0.00011 Tc 8 0 0 8 54.5 35.9844 Tm
[(Ferrar)36.8 (o-Peyr)36.8 (et, et al: Impr)36.8 (ovement in RA)-257.3 (diagnosis)]TJ
0 Tc 0 Tw 61.4375 -0.0313 Td
(281)Tj
ET
0 0 0 0 scn
/GS0 gs
102.25 59.08 407.5 -10.83 re
f*
0.5 w
102.25 59.08 407.5 -10.83 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 g
/GS2 gs
/T1_0 8 Tf
120.092 51 Td
(Personal non-commercial use only. The Journal of Rheumatology Copyright\
\251 2002. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_1 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
83 0 obj
<>
endobj
101 0 obj
<>
endobj
50 0 obj
<>
endobj
44 0 obj
<>
endobj
46 0 obj
<>
endobj
78 0 obj
<>stream
HVpTE=yBB>#O:L/ ɏF§"J5@
]eXD,I)[PEgd) *",0oϛVm9}z@;@A3{r/)W\<(v,[@TV9 (̗
QbQK%/75eԣ9Q5i^^`aΞ8/) +?<"22GM>h(}mږTπ9X7AIWZO:)BVJqbp)I\a+Zc!s:iea,
qIxv<vR:Q^*OE6m
X]8(AYoD/qXkYG@n)1j4
zID0!vHUx28|4+g㪎c$|]U@fpFLz+k}eSb ~a>E#2nmCАn\3wf~78v E,|L)Ureun#yѤ &縉 w^POWqK$e|F9AUԕ%jd%d?21l۫[Kf۰GYhpCd(F2Nr<+Ô9
Ն~|V5џ^vv^t2.aUnKVl8:94&nEaIl)ͬ
cUQ%T!j}G|.0y'rB.Q"dV)-ZUk5NG7CB/BMӊҬ*kj`Ug2IgU`[>O4e,d61:}Ƴtѝ`2#wq!2ϝyDoFLj&St1Cr1W&JZ,v]‸*n[,&dV&Ox*d\.ߖ
UYrl^\5f`K||u
Ik(;ǻNjL$(^úHF.:tYi5oDbJ_ӻWgix:5;ޭkrR q:>!}tm"#MU@fTS#PxL7ur1uLC˲_YzZ,=-E>CͦCoS&8^cfsx<6